[1]

Ma J, Xia J, Miele L, et al. Notch Signaling Pathway in Pancreatic Cancer Progression[J/OL]. Pancreat Disord Ther, 2013, 3(114): 1000114[2018-10-22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3767173/.
[2] Chiang MY, Radojcic V, Maillard I.  Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders[J]. Curr Opin Hematol, 2016, 23(4): 362-370.   doi: 10.1097/MOH.0000000000000254
[3]

Kontomanolis EN, Kalagasidou S, Poulilious S, et al. The Notch Pathway in Breast Cancer Progression[J/OL]. Scientific World Journal, 2018: 2415489[2018-10-22]. https://www.hindawi.com/journals/tswj/2018/2415489/.
[4] Rodriguez JM, Miranda D, Bunout D, et al.  Folates Induce Colorectal Carcinoma HT29 Cell Line Proliferation Through Notch1 Signaling[J]. Nutr Cancer, 2015, 67(4): 706-711.   doi: 10.1080/01635581.2015.1011285
[5] Chiaramonte R, Colombo M, Bulfamante G, et al.  Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1alpha chemokine system[J]. Int J Biochem Cell Biol, 2015, 66: 134-40.   doi: 10.1016/j.biocel.2015.07.015
[6] 杜潇, 程中, 李旸, 等.  γ分泌酶抑制剂DAPT对胰腺癌细胞生长的影响[J]. 四川大学学报(医学版), 2013, 44(5): 699-702.
Du X, Cheng Z, Li Y, et al.  Suppressive Effects of γ-secretase Inhibitor DAPT on the Proliferation of Pancreatic Cancer Cells[J]. J Sichuan Univ(Med Sci), 2013, 44(5): 699-702.
[7] Cook N, Basu B, Smith DM, et al.  A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma[J]. Br J Cancer, 2018, 118(6): 793-801.   doi: 10.1038/bjc.2017.495
[8] Brzozowa-Zasada M, Piecuch A, Michalski M, et al.  Notch and its oncogenic activity in human malignancies[J]. Eur Surg, 2017, 49(5): 199-209.   doi: 10.1007/s10353-017-0491-z
[9]

Feng Z, Xu W, Zhang C, et al. Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer[J/OL]. Oncotarget, 2017, 8(5): 8215-8225[2018-10-22]. http://mct.aacrjournals.org/content/5/3/483.long. DOI: 10.18632/oncotarget.14152.
[10] Wang Z, Zhang Y, Li Y, et al.  Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells[J]. Mol Cancer Ther, 2006, 5(3): 483-493.   doi: 10.1158/1535-7163.MCT-05-0299
[11] Wang L, Dai G, Yang J, et al.  Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097[J]. Med Sci Monit, 2018, 24: 4046-4053.   doi: 10.12659/MSM.909452
[12] Yuan X, Wu H, Xu H, et al.  Notch signaling: an emerging therapeutic target for cancer treatment[J]. Cancer Lett, 2015, 369(1): 20-27.   doi: 10.1016/j.canlet.2015.07.048
[13] Siegel RL, Miller KD, Jemal A.  Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29.   doi: 10.3322/caac.21254
[14] 中国临床肿瘤学会胰腺癌专家委员会.  胰腺癌综合诊治中国专家共识(2014年版)[J]. 临床肝胆病杂志, 2014, 30(10): 970-980.   doi: 10.3969/j.issn.1001-5256.2014.10.002
The Chinese Society of Clinical Oncology Pancreatic Cancer Expert Committee.  Chinese consensus on pancreatic cancer diagnosis and treatment (2014 version)[J]. J Clin Hepatol, 2014, 30(10): 970-980.   doi: 10.3969/j.issn.1001-5256.2014.10.002
[15] Du X, Zhao YP, Zhang TP, et al.  Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer[J]. Arch Med Res, 2014, 45(1): 15-20.   doi: 10.1016/j.arcmed.2013.10.001
[16] Liu F, Wang S.  Molecular cues for development and regeneration of salivary glands[J]. Histol Histopathol, 2014, 29(3): 305-312.   doi: 10.14670/HH-29.305
[17] Dang H, Lin AL, Zhang B, et al.  Role for Notch signaling in salivary acinar cell growth and differentiation[J]. Dev Dyn, 2009, 238(3): 724-731.   doi: 10.1002/dydy.21875